MGC poised for cannabis
March 30, 2016
HIV/AIDS, multiple sclerosis,
epilepsy and cancer patients will
be the first to benefit from the use
of medical cannabis in Australia
according to the first white paper
on the subject produced by the
University of Sydney Community
Placement Program in partnership
with Israeli medical and cosmetic
cannabis company MGC
Pharmaceuticals.
Using the acronym for medical
grade cannabis (MGC) the global
company claims over 40 years
experience with aspirations to
supply the legalised markets with
high quality cannabis products for
the growing worldwide demand.
The company says it controls the
whole product chain, from genetics,
harvesting, extracting to the final
product.
MGC declares years of experience
in the Israeli Medical Cannabis
market, as well as the development
of exclusive strains of high CBD
genetics and first to market
advantages globally.
The medical cannabis market
is estimated to be worth around
US$2.7b and growing rapidly as the
products are more widely legalised.
The jointly prepared white paper
investigates the key challenges,
risks and opportunities associated
with establishing a national
medicinal cannabis scheme in
Australia, intended to act as a
a reference for future policy
discussions in the Australian
medicinal cannabis industry.
Medicinal and scientific
aspects are developed in the
report followed by international
regulatory matters, methodological
approaches for estimating the
potential domestic demand, how
to encourage industry competition,
innovation and economic growth
and finally, areas for further
research.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Mar 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Mar 16
